Clinical Trial Update – Second Generation AirSonea®

Melbourne, Australia and Haifa, Israel - 12 August 2015

iSonea recently advised that the Second Generation AirSonea® Wheeze Monitor has new software to significantly improve the speed of detection and quantification of wheeze. This development was led by our Senior Scientific Advisor, Professor Gavriely M.D., D.Sc. and his research team in Haifa, Israel and was incorporated in the app developed by Two Bulls, a leading app developer with offices in New York, Melbourne and Berlin.

A trial of this product will now be conducted at a leading American University in order to help expedite its FDA clearance. The principal investigator is a renowned respiratory physician. Professor Gavriely has met with the clinical team at the University and reported that the device and app worked well in demonstration with the clinical team and received high rating for its design and finish.

We expect the recruitment of patients will start towards the end of September and the trial should be completed by the end of December 2015. Full details will be advised after the trial receives protocol approval by the Institutional Review Board (Independent Ethics Committee).

All of the company's products use our proprietary Acoustic Respiratory Monitoring (ARM™) technology and all products with the exception of AirSonea have received FDA clearance.

Our AirSonea product incorporates this core technology. As previously advised, our current clinical trial has the objective of showing that the Second Generation AirSonea Wheeze Monitor is at least as accurate in detecting and quantifying wheeze as a consensus of a panel of physicians and trained experts.

Discussions with the potential partners to monetize the business will continue whilst the trial is being conducted.

ENDS.

Contact:

Leon L'Huillier
Chairman
+61 (0)3 9653 9321